The first steps of our process include gene sequencing and annotation of mutation sites of cancer driver genes. Our state-of-the-art equipment can also screen for cancerous mutations in blood samples (liquid biopsy) to detect cancers at an early stage in otherwise healthy individuals.
Our services range from processing raw sequence data, to the provision of clinically meaningful reports. To that end, we make use of the latest advances in big data genomics and bioinformatics in order to appropriately aid hospitals, companies and research institutions in the fight against cancer.
